Note: This document is a translation of a part of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between
the Japanese original and this English translation, the Japanese original shall prevail.

Consolidated Financial Results
for the Three Months Ended June 30, 2024
[Japanese GAAP]
July 31, 2024
Company name: EIKEN CHEMICAL CO.,LTD.
Stock exchange listing: Tokyo
Code number: 4549
URL: https://www.eiken.co.jp
Representative: Tsugunori Notomi
President & CEO
Contact: Hajime Watari
Senior Vice President & Executive Officer
Phone: +81-3-5846-3379
Scheduled date of filing quarterly securities report:
Scheduled date of commencing dividend payments: Availability of supplementary briefing material on quarterly financial results:
Schedule of quarterly financial results briefing session:(Amounts of less than one million yen are rounded down.)
1. Consolidated Financial Results for the Three Months Ended June 30, 2024 (April 1, 2024 to June 30, 2024)(1) Consolidated Operating Results(% indicates changes from the previous corresponding period.)
Profit attributable toOperating profit
Ordinary profit
owners of parentNet sales

Millions of yen% Millions of yen
Three months ended
June 30, 2024
9,519
(3.5)
583
June 30, 2023
9,864
(11.1)
1,052(Note) Comprehensive income:Three months ended June 30, 2024:
Three months ended June 30, 2023:

Basic earnings
per share
Three months ended
June 30, 2024
June 30, 2023

% Millions of yen(44.6)(62.4)¥¥% Millions of yen

641(41.0)
1,087(61.8)
547 million [797 million [486770(31.4) %](64.3) %]%(36.8)(64.5)

Diluted earnings pershare
Yen

Yen

14.0720.82

13.95
20.63

(2) Consolidated Financial Position
Total assets
Millions of yen
As ofJune 30, 2024
61,189March 31, 2024
61,651(Reference) Equity: As of June 30, 2024:
As of March 31, 2024:

Net assets

Capital adequacy ratio

Millions of yen¥¥

45,61845,97145,260 million
45,613 million

Net assets per share%

Yen

74.0
74.0

1,308.20
1,318.38

2. Dividends
1stquarter-end

Annual dividends
2nd
3rd
quarter-end
quarter-end

Year-end

TotalYen

Yen

Yen

Yen

Yen

Fiscal year ended March 31, 2024-25.00-26.00

51.00

Fiscal year ending March 31, 2025

26.00

-27.00

53.00

Fiscal year ending March 31, 2025
(Forecast)(Note) Revision to the forecast for dividends announced most recently:
No(Note) Breakdown of the 1st quarter dividend for the fiscal year ending March 31, 2025 :Commemorative dividend- yenSpecial dividend- yen

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2025(April 1, 2024 to March 31, 2025)(% indicates changes from the previous corresponding period.)
Profit attributable toBasic earnings
Operating profit
Ordinary profit
owners ofper shareparentNet sales
Millions ofyen%Millions ofyen%

Six months ending
21,500
6.1
2,870
33.6
September 30, 2024
Full year
43,100
7.6
5,660
67.6
(Note) Revision to the financial results forecast announced most recently:

Millions ofyen%Millions ofyen%

Yen

2,830

27.2

2,230

37.7

64.45

5,620
No

57.5

4,480

70.1

129.49* Notes:(1) Changes in significant subsidiaries during the three months ended June 30, 2024
(changes in specified subsidiaries resulting in changes in scope of consolidation):
New(Company name:(Company name:
Exclusion:(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements:(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement
1) Changes in accounting policies due to the revision of accounting standards:
No2) Changes in accounting policies other than 1) above:No3) Changes in accounting estimates:
No4) Retrospective restatement:No(4) Total number of issued shares (common shares)
1) Total number of issued shares at the end of the period (including treasury shares):
June 30, 2024:
38,541,438shares
March 31, 2024:
40,041,438shares
2) Number of treasury shares at the end of the period:
June 30, 2024:
3,943,508shares
March 31, 2024:
5,443,508shares
3) Average number of shares outstanding during the period:
Three months ended June 30, 2024:
Three months ended June 30, 2023:

34,597,930shares
37,028,813shares

)
)
Yes

Table of Contents - Attachments
1. Overview of Consolidated Business Performance ..................................................................................2(1) Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year ........2(2) Summary of Consolidated Financial Position for The First Quarter of Tthe Current Fiscal Year .............2(3) Qualitative Information Regarding Forecasts for Consolidated Business Performance .....................3
2. Quarterly Consolidated Financial Statements and Principal Notes .........................................................4(1) Quarterly Consolidated Balance Sheets ..............................................................................................4(2) Quarterly Consolidated Statements of Income and Comprehensive Income ......................................6
Quarterly Consolidated Statements of Income
For the three months ....................................................................................................................6Quarterly Consolidated Statements of Comprehensive Income
For the three months ....................................................................................................................7(3) Notes to Quarterly Consolidated Financial Statements .......................................................................8(Notes on going concern assumption) ............................................................................................8(Accounting methods adopted particularly for the preparation of quarterly consolidated financialstatements) ......................................................................................................................................8(Notes in case of significant changes in shareholders’ equity) .......................................................8(Notes on Cash Flow Statement) ......................................................................................................8(Segment information) .....................................................................................................................81

1. Overview of Consolidated Business Performance(1) Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year
During the first quarter of the current fiscal year, the domestic and overseas economies remained unstable
due to downside risks owing to surging resource prices and the effects of monetary tightening.
The business environment became increasingly severe in the clinical diagnostics industry due to measures tocap medical expenses and rising costs such as for logistics and raw material procurement, etc., on account of yen
depreciation and high crude oil prices. Corporations are being forced to focus on greater cost competitivenessand to actively expand overseas.
In the context of this business environment, the Eiken Group is implementing key measures focused on thethree key business fields of “Contribution to cancer prevention and treatment,” “Contribution to the eradicationand control of infectious diseases,” and “Provision of products and services useful for health care” and striving
to achieve sustainable growth and steadily enhance profitability for the Group as a whole, in accordance withthe Medium-term Management Plan established based on the Group’s management framework “EIKEN ROAD
MAP 2030.”
In addition, as a Group with a mission to protect the health of people worldwide, the Eiken Group is addressing
issues not only in “Medical” but also in the “Environment,” “Society,” and “Governance.” Through this, westrive to further enhance our corporate value and achieve a sustainable society.
The net sales for the consolidated fiscal year under review declined to 9,519 million yen (down 3.5% yearon-year) due to a decrease in sales of fecal immunochemical test reagents for overseas markets. For net salesby product class and type, sales of microbiological testing reagents were 1,058 million yen (up 1.9% year-onyear) due to increased sales of the rapid diagnostic kits for our new products (Immunocatch –Strep A,Immunocatch –Adeno). Sales of urinalysis reagents were 1,122 million yen (up 13.0% year-on-year) due togrowth in sales of urine test strips for both domestic and overseas markets. For sales of immunological andserological reagents were 5,602 million yen (down 4.0% year-on-year) due to a decrease in sales of overseasmarkets, despite sales of fecal immunochemical test reagents for domestic markets remained strong. Sales ofclinical chemistry reagents were 150 million yen (up 0.3% year-on-year) and sales of the equipment andculture medium for food and environment related category were 512 million yen (up 6.6% year-on-year). Salesin other category (medical devices, genetic-related products, etc.) were 1,072 million yen (down 21.6% yearon-year) due to a decrease in sales for COVID-19 detection reagents.
Overseas sales were 2,113 million yen (down 16.3% year-on-year) due to a decrease in sales of fecal
immunochemical test reagents, despite strong growth in sales of urinalysis reagents.
Regarding profit, due to changes in the sales mix, including a decrease in sales of fecal immunochemical test
reagents for overseas markets, operating profit was 583 million yen (down 44.6% year-on-year), ordinary
profit was 641 million yen (down 41.0% year-on-year), and profit attributable to owners of parent was 486
million yen (down 36.8% year-on-year).
(2) Summary of Consolidated Financial Position for The First Quarter of Tthe Current Fiscal YearThe financial position at the end of the first quarter of the consolidated accounting period under review wasas follows.
When compared to the end of the previous consolidated fiscal year ,total assets decreased by 461 million yen,liabilities decreased by 109 million yen, and net assets decreased by 352 million yen.
Major increases and decreases in the category of assets were a decrease of 2,512 million yen in cash anddeposits and a decrease of 444 million yen in notes and accounts receivable - trade, and contract assets. Inaddition, property, plant and equipment increased by 1,952 million yen due to the recording of construction inprogress accompanying the payment of construction expenses for the new manufacturing building at Nogi
Division. In the category of liabilities, provision for bonuses decreased by 328 million yen due to payment ofbonuses. In the category of net assets, despite the recording of profit attributable to owners of parent,
shareholders' equity decreased by 412 million yen due to the payment of dividends. Retained earnings andtreasury shares decreased by 1,567 million yen each due to the cancellation of treasury shares.
2

As a result, the equity ratio was 74.0%, unchanged from the end of the previous fiscal year.

(3) Qualitative Information Regarding Forecasts for Consolidated Business Performance
For the consolidated financial results forecasts for the six months ending September 30, 2024 and theconsolidated fiscal year ending March 31, 2024, there has been no change in the financial forecast announced
on May 9, 2024.

3

２.Quarterly Consolidated Financial Statements and Principal Notes(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2024

As of June 30, 2024

AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade, and contract
assetsMerchandise and finished goods

16,308

13,795

12,482

12,037

4,170

4,107

Work in process

2,035

2,269

Raw materials and supplies

1,892

1,991

971
(7)

977
(7)

37,85135,17025,811(13,821)25,961(14,077)

Buildings and structures, net

11,98911,884

Machinery, equipment and vehicles
Accumulated depreciation

7,638(6,115)

8,007(6,245)

1,522

1,761

Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation

Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net

5,371

5,623

(4,374)(4,491)

996

1,132

1,928
286

1,928
251

Accumulated depreciation

(133)

(111)

Leased assets, net

153

140

Construction in progress

414

2,110

17,005

18,957

Land
Leased assetsTotal property, plant and equipment
Intangible assets
Investments and other assets
Long-term time deposits
Other
Allowance for doubtful accounts

792

770

1,900
4,125(23)1,900
4,414(23)

Total investments and other assets

6,001

6,290

23,79926,01961,651

61,189Total non-current assets
Total assets

4

(Millions of yen)
As of March 31, 2024

As of June 30, 2024

Liabilities
Current liabilities
Notes and accounts payable - trade

4,648

4,371

2,759

3,094

674

74
346

Other

3,269

3,306

Total current liabilities

11,351

11,1923,000

3,000Electronically recorded obligations - operating
Income taxes payable
Provision for bonuses

Non-current liabilities
Bonds payable
Asset retirement obligations
Other
Total non-current liabilities
Total liabilities

3535

1,293

1,342

4,329

4,378

15,68015,571

6,897
7,892
35,801

6,897
7,892
33,821

Net assets
Shareholders' equity
Share capital
Capital surplus
Retained earnings
Treasury shares(5,686)(4,119)Total shareholders' equity

44,90444,491

Accumulated other comprehensive income
Valuation difference on available-for-sale securities

3533

Foreign currency translation adjustment
Remeasurements of defined benefit plans

353
319

426
309

Total accumulated other comprehensive income

708

768

Share acquisition rights
Total net assets
Total liabilities and net assets

5358

358

45,97145,61861,651

61,189(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income (For the three months)(Millions of yen)
For the three months
ended June 30, 2023

For the three months
ended June 30, 2024

Net sales

9,864

9,519

Cost of sales

5,6815,566

Gross profit

4,183

3,953

Selling, general and administrative expenses

3,130

3,369

Operating profit

1,052

583

Interest income

12Dividend income
Rental income

2433

Subsidy income

1031

Foreign exchange gains
Other

12818
11

Total non-operating income

4070

440

8

Non-operating income

Non-operating expenses
Interest expenses
Other
Total non-operating expenses

512

1,087

641

1-

Gain on sale of investment securities-

3

Total extraordinary income

1351

0510

Ordinary profit
Extraordinary income
Gain on sale of non-current assets

Extraordinary losses
Loss on sale and retirement of non-current assets
Total extraordinary losses
Profit before income taxes

1,037

644

Income taxes

266

158

Profit770486--770486

Profit attributable to non-controlling interests
Profit attributable to owners of parent

6

Quarterly Consolidated Statements of Comprehensive Income (For the three months)(Millions of yen)
For the three months
ended June 30, 2023
Profit

For the three months
ended June 30, 2024
770486

030

(2)
72

Remeasurements of defined benefit plans, net of tax

(3)

(10)

Total other comprehensive income

2660

797

547

797

547--

Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment

Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controllinginterests7(3) Notes to Quarterly Consolidated Financial Statements(Notes on going concern assumption)
Not applicable.
(Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements)(Tax expense calculation)Tax expenses on profit before income taxes are calculated by multiplying profit before income taxes by thereasonably estimated effective tax rate for the consolidated fiscal year including the first quarter of theconsolidated accounting period under review after applying tax effect accounting.
(Notes in case of significant changes in shareholders’ equity)(Retirement of treasury shares)
In accordance with resolution of a meeting of the Board of Directors held on April 24, 2024, the Company
retired 1,500,000 treasury shares on April 26, 2024. As a result, for the first quarter of the current fiscal year,retained earnings and treasury shares each decreased by 1,567 million yen.
(Notes on Cash Flow Statement)
Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year are not prepared.
Depreciation (Including depreciation of intangible assets.) for the first quarter of the current fiscal year is as follows.

Depreciation

Previous consolidated fiscal(From April 1, 2023
to June 30, 2023)
544(Millions of yen)
Current consolidated fiscalyear(From April 1, 2024
to June 30, 2024)
546(Segment information)
Ⅰ Previous consolidated fiscal year(From April 1, 2023 to June 30, 2023)
The Group is a single segment of the reagents business, so it is omitted.
Ⅱ Current consolidated fiscal year(From April 1, 2024 to June 30, 2024)
The Group is a single segment of the reagents business, so it is omitted.

8